FOCU.SE trial: a nationwide Swedish drug repurposing protocol and research framework

Authors

  • Edvard Abel Department of Oncology, Institute of Clinical Sciences, University of Gothenburg, Gothenburg, Sweden; Sahlgrenska Comprehensive Cancer Centre, Department of Oncology, Sahlgrenska University Hospital, Region Västra Götaland, Gothenburg, Sweden https://orcid.org/0000-0002-0482-2015
  • Päivi Östling Science for Life Laboratory (SciLifeLab), Department of Oncology-Pathology Karolinska Institutet, Stockholm. Sweden; Karolinska Comprehensive Cancer Project Unit, Karolinska University Hospital, Stockholm, Sweden https://orcid.org/0000-0001-5501-466X
  • Ebba Hallersjö Hult Stockholm School of Economics Institute for Research, Stockholm, Sweden https://orcid.org/0009-0005-7247-9510
  • Katarzyna Kulbacka Sahlgrenska Comprehensive Cancer Centre, Department of Oncology, Sahlgrenska University Hospital, Region Västra Götaland, Gothenburg, Sweden https://orcid.org/0000-0002-9195-2300
  • Haris Babacic Department of Oncology and Pathology, Karolinska Institutet and SciLifeLab, Stockholm, Sweden
  • Annika Baan Sahlgrenska Comprehensive Cancer Centre, Department of Oncology, Sahlgrenska University Hospital, Region Västra Götaland, Gothenburg, Sweden
  • Ana Carneiro Department of Oncology, Lund University Cancer Center, Institution för Clinical Sciences, Lunds University, Lund, Sweden; Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital Comprehensive Cancer Center, Skåne University Hospital, Lund, Sweden
  • Luigi De Petris Center for Clinical Cancer Studies, Karolinska University Hospital, Stockholm, Sweden; Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden
  • Henrik Fagman Department of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Department of Clinical Pathology, Sahlgrenska University Hospital, Gothenburg, Sweden
  • Signe Friesland Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden; Department of Head-neck-, Lung-cancer and Melanoma, Theme Cancer, Karolinska University Hospital, Stockholm, Sweden
  • Oskar Frisell The Swedish Institute for Health Economics (IHE), Lund, Sweden; Department of Learning, Informatics, Management and Ethics (LIME), Karolinska Institutet, Stockholm, Sweden
  • Mats Hellström Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden
  • Gabriel Lindahl Department of Oncology and Department of Biomedical and Clinical Sciences, Linköping University, Linköping Sweden
  • Katarina Steen Carlsson The Swedish Institute for Health Economics (IHE), Lund, Sweden; Department of Clinical Sciences, Malmö, Lund University, Sweden s. Department of Research, development, education and innovation, Skåne University Hospital, Lund, Sweden
  • David Tamborero Department of Oncology and Pathology, Karolinska Institutet and SciLifeLab, Stockholm, Sweden; Division of Pathology, Karolinska University Hospital, Stockholm, Sweden
  • Antonios Valachis Department of Oncology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden
  • Daniel Öhlund Department of Diagnostics and Intervention, and Wallenberg Centre for Molecular Medicine, Umeå University, Umeå, Sweden https://orcid.org/0000-0002-5847-2778
  • Janne Lehtiö Department of Oncology and Pathology, Karolinska Institutet and SciLifeLab, Stockholm, Sweden; Division of Pathology, Karolinska University Hospital, Stockholm, Sweden https://orcid.org/0000-0002-8100-9562
  • Richard Rosenquist Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden; Clinical Genetics and Genomics, Karolinska University Hospital, Stockholm, Sweden https://orcid.org/0000-0002-0211-8788
  • Anders Edsjö Department of Clinical Genetics, Pathology and Molecular Diagnostics, Skåne University Hospital, Region Skåne, Lund, Sweden; Division of Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden. https://orcid.org/0000-0001-8783-8284

DOI:

https://doi.org/10.2340/ao.v65.45355

Keywords:

Precision medicine, biomarker profiling, drug repurposing, Targeted therapy, platform trial, national infrastructure, multimodal analysis, Sweden, PRIME-ROSE consortium, cancer genomics, proteomics

Downloads

Download data is not yet available.

References

Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31–46.

https://doi.org/10.1158/2159-8290.CD-21-1059 DOI: https://doi.org/10.1158/2159-8290.CD-21-1059

Zerdes I, Filis P, Fountoukidis G, El-Naggar AI, Kalofonou F, D’Alessio A, et al. Comprehensive genome profiling for treatment decisions in patients with metastatic tumors: real-world evidence meta-analysis and registry data implementation. J Natl Cancer Inst. 2025;117(6):1117–24.

https://doi.org/10.1093/jnci/djaf015 DOI: https://doi.org/10.1093/jnci/djaf015

Hoes LR, van Berge Henegouwen JM, van der Wijngaart H, Zeverijn LJ, van der Velden DL, van de Haar J, et al. Patients with rare cancers in the drug rediscovery protocol (DRUP) benefit from genomics-guided treatment. Clin Cancer Res. 2022;28(7):1402–11.

https://doi.org/10.1158/1078-0432.CCR-21-3752 DOI: https://doi.org/10.1158/1078-0432.CCR-21-3752

Mangat PK, Halabi S, Bruinooge SS, Garrett-Mayer E, Alva A, Janeway KA, et al. Rationale and design of the targeted agent and profiling utilization registry (TAPUR) study. JCO Precis Oncol. 2018;2018(2):1–14.

https://doi.org/10.1200/PO.18.00122 DOI: https://doi.org/10.1200/PO.18.00122

Helland A, Russnes HG, Fagereng GL, Al-Shibli K, Andersson Y, Berg T, et al. Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway. J Transl Med. 2022;20(1):225.

https://doi.org/10.1186/s12967-022-03432-5 DOI: https://doi.org/10.1186/s12967-022-03432-5

Kringelbach T, Hojgaard M, Rohrberg K, Spanggaard I, Laursen BE, Ladekarl M, et al. ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling – a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial. BMC Cancer. 2023;23(1):182.

https://doi.org/10.1186/s12885-023-10632-9 DOI: https://doi.org/10.1186/s12885-023-10632-9

Jalkanen K, Alanne E, Iivanainen SME, Kääriäinen OS, Tanner MME, Färkkilä A, et al. FINPROVE: the Finnish national study to facilitate patient access to targeted anti-cancer drugs – preliminary data after two years of enrollment. Ann Oncol. 2024;35:S246.

https://doi.org/10.1016/j.annonc.2024.08.089 DOI: https://doi.org/10.1016/j.annonc.2024.08.089

Ny L, Fagman H, Botling J, Mantovaara L, Asplund P, Karlsson H, et al. Feasibility and outcome of genomics-guided treatment selection in advanced cancer-the MEGALiT explorative clinical trial. Acta Oncol. 2025;64:742–50.

https://doi.org/10.2340/1651-226X.2025.43366 DOI: https://doi.org/10.2340/1651-226X.2025.43366

Tasken K, Haj Mohammad SF, Fagereng GL, Sorum Falk R, Helland A, van Waalwijk van Doorn-Khosrovani SB, et al. PCM4EU and PRIME-ROSE: collaboration for implementation of precision cancer medicine in Europe. Acta Oncol. 2024;63:385–91.

https://doi.org/10.2340/1651-226X.2024.34791 DOI: https://doi.org/10.2340/1651-226X.2024.34791

Park JJH, Hsu G, Siden EG, Thorlund K, Mills EJ. An overview of precision oncology basket and umbrella trials for clinicians. CA Cancer J Clin. 2020;70(2):125–37.

https://doi.org/10.3322/caac.21600 DOI: https://doi.org/10.3322/caac.21600

Genomic Medicine Sweden. GMS560: a broad targeted NGS gene panel for comprehensive genomic profiling of solid tumors. 2023. Accessed January 2026. https://genomicmedicine.se/wp-content/uploads/2023/11/GMS560_ synopsis.pdf

Tamborero D, Dienstmann R, Rachid MH, Boekel J, Lopez-Fernandez A, Jonsson M, et al. The molecular tumor board portal supports clinical decisions and automated reporting for precision oncology. Nat Cancer. 2022;3(2):251–61.

https://doi.org/10.1038/s43018-022-00332-x DOI: https://doi.org/10.1038/s43018-022-00332-x

Mateo J, Chakravarty D, Dienstmann R, Jezdic S, Gonzalez-Perez A, Lopez-Bigas N, et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann Oncol. 2018;29(9):1895–902.

https://doi.org/10.1093/annonc/mdy263 DOI: https://doi.org/10.1093/annonc/mdy263

Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10(1):1–10.

https://doi.org/10.1016/0197-2456(89)90015-9 DOI: https://doi.org/10.1016/0197-2456(89)90015-9

Carswell O, Morgan L, Wait S, Hallersjö Hult E, Edsjö A, Asplund P. Building health system readiness for precision cancer medicine through clinical trials: an implementation framework. Version 1. London: The Health Policy Partnership; 2024.

Downloads

Published

2026-04-13

How to Cite

Abel, E., Östling, P., Hallersjö Hult, E., Kulbacka, K., Babacic, H., Baan, A., … Edsjö, A. (2026). FOCU.SE trial: a nationwide Swedish drug repurposing protocol and research framework. Acta Oncologica, 65, 268–272. https://doi.org/10.2340/ao.v65.45355

Issue

Vol. 65 (2026): Acta Oncologica

Section

Letter

Categories

License

Copyright (c) 2026 Edvard Abel, Päivi Östling, Ebba Hallersjö Hult, Katarzyna Kulbacka, Haris Babacic, Annika Baan, Ana Carneiro, Luigi De Petris, Henrik Fagman, Signe Friesland, Oskar Frisell, Mats Hellström, Gabriel Lindahl, Katarina Steen Carlsson, David Tamborero, Antonios Valachis, Daniel Öhlund, Janne Lehtiö, Richard Rosenquist, Anders Edsjö

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.